Using Raman Spectroscopy to Diagnose Kidney Diseases
Research on Raman Spectroscopy Detection Technology in Kidney Disease Diagnosis
This study is testing a new way to diagnose kidney diseases by analyzing urine and blood samples from patients with specific kidney conditions to see if it can help identify the diseases more accurately.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Sex | All |
| Sponsor | Qianfoshan Hospital Academic / other |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT06760845 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect serum and morning urine samples from patients diagnosed with IgA nephropathy, membranous nephropathy, diabetic nephropathy, and focal segmental glomerulosclerosis at Qianfoshan Hospital in Shandong Province. The samples will be analyzed using Raman spectroscopy to obtain spectral data, which will be processed to identify chemical compounds associated with these kidney diseases. The study will establish calibration curves to quantitatively analyze the concentration of specific analytes in the samples, potentially leading to improved diagnostic methods for these conditions.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with specific types of nephropathy confirmed by renal biopsy.
Not a fit: Patients with secondary causes of membranous nephropathy or severe infections and cardiovascular diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of kidney disease diagnoses through non-invasive methods.
How similar studies have performed: While Raman spectroscopy has been explored in various diagnostic contexts, this specific application for kidney diseases is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 years or older; 2. Patients diagnosed with IgA nephropathy, idiopathic membranous nephrop, diabetic nephropathy, or focal segmental glomerulosclerosis confirmed by renal biopsy; 3. Patients who have not received hormone and/or immunosup therapy before the renal biopsy; Exclusion Criteria: 1. Presence of factors causing secondary membranous nephropathy: such as autoimmune diseases (systemic lupus erythematosus),/infections (viral hepatitis), drugs or toxins, etc.; 2. Severe infection: clinical manifestations such as fever, cough and sputum, throat, abdominal pain, diarrhea, boils and other skin and soft tissue infections, with white blood cell count in blood routine exceeding the normal range (10×09/L); 3. Severe cardiovascular disease: including chronic heart failure of grade 3 or above and various arrhythmias; 4. Infect diseases: active phase of various types of hepatitis, AIDS, syphilis, etc.; 5. Evidence of tumor: already diagnosed with a certain tumor or manifestations, tumor markers, etc. indicating the possibility of a tumor; 6. Patients with incomplete data or missed diagnosis.
Where this trial is running
Jinan, Shandong
- Shandong Second Medical University. No.7166 Baotong West Street, Weifang, Shandong, 261053, China. — Jinan, Shandong, China (Recruiting)
Study contacts
- Study coordinator: Zunsong Wang, Dr
- Email: wzsong3@163.com
- Phone: 15966608835
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.